Skip to main content

Search form

You are here

Takuya Osada, MD, PhD

Associate Professor of Surgery
Division: 
Surgical Sciences
Faculty Lab: 
Center for Applied Therapeutics
Office: 401 Med Sci Res Bldg, Durham, NC 27710
Campus Mail: DUMC Box 2606 Med Ctr, Durham, NC 27710

Education and Training

  • Ph.D., University of Tokyo (Japan), 1997
  • M.D., University of Tokyo (Japan), 1986

Selected Grants

Publications

Osada, T, Kaneko, K, Gwin, WR, Morse, MA, Hobeika, A, Pogue, BW, Hartman, ZC, Hughes, PF, Haystead, T, and Lyerly, HK. "In Vivo Detection of HSP90 Identifies Breast Cancers with Aggressive Behavior." Clinical cancer research : an official journal of the American Association for Cancer Research 23, no. 24 (December 2017): 7531-7542.

Full Text

Crowe, LB, Hughes, PF, Alcorta, DA, Osada, T, Smith, AP, Totzke, J, Loiselle, DR, Lutz, ID, Gargesha, M, Roy, D, Roques, J, Darr, D, Lyerly, HK, Spector, NL, and Haystead, TAJ. "A Fluorescent Hsp90 Probe Demonstrates the Unique Association between Extracellular Hsp90 and Malignancy in Vivo." ACS chemical biology 12, no. 4 (April 2017): 1047-1055.

Full Text

Kaneko, K, Osada, T, Freimark, BD, and Lyerly, HK. "Abstract B36: Modulating the tumor microenvironment to enhance cancer immunotherapy by inducing phosphatidylserine expression on the tumor surface." February 2017.

Full Text

Osada, T, Morse, MA, Hobeika, A, Diniz, MA, Gwin, WR, Hartman, Z, Wei, J, Guo, H, Yang, X-Y, Liu, C-X, Kaneko, K, Broadwater, G, and Lyerly, HK. "Vaccination targeting human HER3 alters the phenotype of infiltrating T cells and responses to immune checkpoint inhibition." Oncoimmunology 6, no. 6 (January 2017): e1315495-.

Full Text

Vaidyanathan, G, McDougald, D, Choi, J, Koumarianou, E, Weitzel, D, Osada, T, Lyerly, HK, and Zalutsky, MR. "Preclinical Evaluation of 18F-Labeled Anti-HER2 Nanobody Conjugates for Imaging HER2 Receptor Expression by Immuno-PET." Journal of nuclear medicine : official publication, Society of Nuclear Medicine 57, no. 6 (June 2016): 967-973.

Full Text

Oldham, M, Yoon, S, Meng, B, Fathi, Z, Beyer, W, Adamson, J, Alcorta, D, Osada, T, Lyerly, K, Dewhirst, M, Fecci, P, Walder, H, and Spector, N. "WE-FG-BRA-01: Cancer Treatment Utilizing Photo-Activation of Psoralen with KV X-Rays." Medical physics 43, no. 6 (June 2016): 3823-.

Full Text

Oldham, M, Yoon, P, Fathi, Z, Beyer, WF, Adamson, J, Liu, L, Alcorta, D, Xia, W, Osada, T, Liu, C, Yang, XY, Dodd, RD, Herndon, JE, Meng, B, Kirsch, DG, Lyerly, HK, Dewhirst, MW, Fecci, P, Walder, H, and Spector, NL. "X-Ray Psoralen Activated Cancer Therapy (X-PACT)." PloS one 11, no. 9 (January 2016): e0162078-.

Full Text

Ren, XR, Wang, J, Osada, T, Mook, RA, Morse, MA, Barak, LS, Lyerly, HK, and Chen, W. "Perhexiline promotes HER3 ablation through receptor internalization and inhibits tumor growth." Breast cancer research : BCR 17, no. 1 (December 2015): 528-.

Scholars@Duke

Vaidyanathan, G, McDougald, D, Choi, J, Koumarianou, E, Pruszynski, M, Osada, T, Lyerly, H, Lahoutte, T, and Zalutsky, MR. "An Anti-HER2 Nanobody Labeled with 18F Using a Residualizing Label for Assessing HER2 Status." October 2015.

Scholars@Duke

Osada, T, Patel, SP, Hammond, SA, Osada, K, Morse, MA, and Lyerly, HK. "CEA/CD3-bispecific T cell-engaging (BiTE) antibody-mediated T lymphocyte cytotoxicity maximized by inhibition of both PD1 and PD-L1." Cancer immunology, immunotherapy : CII 64, no. 6 (June 2015): 677-688.

Full Text

Pages